Home › Trial NCT03469713
Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma
- Trial IDNCT03469713
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorGruppo Oncologico Italiano di Ricerca Clinica
- Enrollment69
- Start date2017-07-14
- ConditionsRenal Cancer Metastatic
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.